Suggested remit - To appraise the clinical and cost effectiveness of rovalpituzumab tesirine within its marketing authorisation for treating small-cell lung cancer after 2 therapies.
Status In progress
Process STA
ID number 1288

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 06 February 2018 - 06 March 2018

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 April 2017 In progress, DH Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance